インスリンバイオシミラーのグローバル市場 2021年：企業別、地域別、種類・用途別

• 英文タイトル：Global Insulin Biosimilars Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-203B16440 • 出版社/出版日：GlobalInfoResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

インスリンバイオシミラー市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のインスリンバイオシミラーの市場規模は2020年のxxx米ドルから2021年にはxxx米ドルと推定され、2020年から2021年の間にxxx％の変化があります。世界のインスリンバイオシミラーの市場規模は次の5年間でxxx％のCAGRで成長すると予想されます。 インスリンバイオシミラー市場は種類と用途によって区分されます。2016年～2026年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・速効型バイオシミラー、長時間作用型バイオシミラー、プレミックスバイオシミラー 用途別セグメントは次のように区分されます。 ・I型糖尿病、II型糖尿病 世界のインスリンバイオシミラー市場の主要な市場プレーヤーは以下のとおりです。 ・Sanofi S.A.、Boehringer Ingelheim、Eli Lilly & Co.、Novo Nordisk A/S、Biocon、Geropharm、Wockhardt、Gan&Lee Pharmaceuticals、The United Laboratories International、Tonghua Dongbao Pharmaceutical 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計14章あります。 ・第1章では、インスリンバイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なインスリンバイオシミラーメーカーの企業概要、2019年～2021年までのインスリンバイオシミラーの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なインスリンバイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2016年～2026年までの地域別インスリンバイオシミラーの販売量、売上、成長性を示しています。 ・第5、6章では、2016年～2026年までのインスリンバイオシミラーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2016年～2021年までの世界の主要国での販売量、売上、市場シェア、並びに2021年～2026年までの主要地域でのインスリンバイオシミラー市場予測を収録しています。 ・第12、13、14章では、インスリンバイオシミラーの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi S.A.、Boehringer Ingelheim、Eli Lilly & Co.、Novo Nordisk A/S、Biocon、Geropharm、Wockhardt、Gan&Lee Pharmaceuticals、The United Laboratories International、Tonghua Dongbao Pharmaceutical ・メーカー別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：速効型バイオシミラー、長時間作用型バイオシミラー、プレミックスバイオシミラー ・用途別分析2016年-2026年：I型糖尿病、II型糖尿病 ・インスリンバイオシミラーの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・インスリンバイオシミラーのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・インスリンバイオシミラーのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・インスリンバイオシミラーの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・インスリンバイオシミラーの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Insulin Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Insulin Biosimilars size is estimated to be million in 2021 from USD million in 2020, with a change of % between 2020 and 2021. The global Insulin Biosimilars market size is expected to grow at a CAGR of % for the next five years.

Market segmentation
Insulin Biosimilars market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars

Market segment by Application can be divided into
Type I Diabetes
Type II Diabetes

The key market players for global Insulin Biosimilars market are listed below:
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Insulin Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Insulin Biosimilars, with price, sales, revenue and global market share of Insulin Biosimilars from 2019 to 2021.
Chapter 3, the Insulin Biosimilars competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Insulin Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Insulin Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Insulin Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Insulin Biosimilars Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Rapid-Acting Biosimilars
1.2.3 Long-Acting Biosimilars
1.2.4 Premixed Biosimilars
1.3 Market Analysis by Application
1.3.1 Overview: Global Insulin Biosimilars Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Global Insulin Biosimilars Market Size & Forecast
1.4.1 Global Insulin Biosimilars Sales in Value (2016-2026))
1.4.2 Global Insulin Biosimilars Sales in Volume (2016-2026)
1.4.3 Global Insulin Biosimilars Price by Type (2016-2026) & (US$/Unit)
1.5 Global Insulin Biosimilars Production Capacity Analysis
1.5.1 Global Insulin Biosimilars Total Production Capacity (2016-2026)
1.5.2 Global Insulin Biosimilars Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Insulin Biosimilars Market Drivers
1.6.2 Insulin Biosimilars Market Restraints
1.6.3 Insulin Biosimilars Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi S.A.
2.1.1 Sanofi S.A. Details
2.1.2 Sanofi S.A. Major Business
2.1.3 Sanofi S.A. Insulin Biosimilars Product and Services
2.1.4 Sanofi S.A. Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business
2.2.3 Boehringer Ingelheim Insulin Biosimilars Product and Services
2.2.4 Boehringer Ingelheim Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Eli Lilly & Co.
2.3.1 Eli Lilly & Co. Details
2.3.2 Eli Lilly & Co. Major Business
2.3.3 Eli Lilly & Co. Insulin Biosimilars Product and Services
2.3.4 Eli Lilly & Co. Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Novo Nordisk A/S
2.4.1 Novo Nordisk A/S Details
2.4.2 Novo Nordisk A/S Major Business
2.4.3 Novo Nordisk A/S Insulin Biosimilars Product and Services
2.4.4 Novo Nordisk A/S Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Biocon
2.5.1 Biocon Details
2.5.2 Biocon Major Business
2.5.3 Biocon Insulin Biosimilars Product and Services
2.5.4 Biocon Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Geropharm
2.6.1 Geropharm Details
2.6.2 Geropharm Major Business
2.6.3 Geropharm Insulin Biosimilars Product and Services
2.6.4 Geropharm Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Wockhardt
2.7.1 Wockhardt Details
2.7.2 Wockhardt Major Business
2.7.3 Wockhardt Insulin Biosimilars Product and Services
2.7.4 Wockhardt Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Gan&Lee Pharmaceuticals
2.8.1 Gan&Lee Pharmaceuticals Details
2.8.2 Gan&Lee Pharmaceuticals Major Business
2.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
2.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 The United Laboratories International
2.9.1 The United Laboratories International Details
2.9.2 The United Laboratories International Major Business
2.9.3 The United Laboratories International Insulin Biosimilars Product and Services
2.9.4 The United Laboratories International Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Tonghua Dongbao Pharmaceutical
2.10.1 Tonghua Dongbao Pharmaceutical Details
2.10.2 Tonghua Dongbao Pharmaceutical Major Business
2.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
2.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Insulin Biosimilars Sales by Manufacturer
3.1 Global Insulin Biosimilars Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Insulin Biosimilars Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Insulin Biosimilars
3.4 Market Concentration Rate
3.4.1 Top 3 Insulin Biosimilars Manufacturer Market Share
3.4.2 Top 6 Insulin Biosimilars Manufacturer Market Share
3.5 Global Insulin Biosimilars Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Insulin Biosimilars Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Insulin Biosimilars Market Size by Region
4.1.1 Global Insulin Biosimilars Sales in Volume by Region (2016-2026)
4.1.2 Global Insulin Biosimilars Revenue by Region (2016-2026)
4.2 North America Insulin Biosimilars Revenue (2016-2026)
4.3 Europe Insulin Biosimilars Revenue (2016-2026)
4.4 Asia-Pacific Insulin Biosimilars Revenue (2016-2026)
4.5 South America Insulin Biosimilars Revenue (2016-2026)
4.6 Middle East and Africa Insulin Biosimilars Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Insulin Biosimilars Sales in Volume by Type (2016-2026)
5.2 Global Insulin Biosimilars Revenue by Type (2016-2026)
5.3 Global Insulin Biosimilars Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Insulin Biosimilars Sales in Volume by Application (2016-2026)
6.2 Global Insulin Biosimilars Revenue by Application (2016-2026)
6.3 Global Insulin Biosimilars Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Insulin Biosimilars Sales by Type (2016-2026)
7.2 North America Insulin Biosimilars Sales by Application (2016-2026)
7.3 North America Insulin Biosimilars Market Size by Country
7.3.1 North America Insulin Biosimilars Sales in Volume by Country (2016-2026)
7.3.2 North America Insulin Biosimilars Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Insulin Biosimilars Sales by Type (2016-2026)
8.2 Europe Insulin Biosimilars Sales by Application (2016-2026)
8.3 Europe Insulin Biosimilars Market Size by Country
8.3.1 Europe Insulin Biosimilars Sales in Volume by Country (2016-2026)
8.3.2 Europe Insulin Biosimilars Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Insulin Biosimilars Sales by Type (2016-2026)
9.2 Asia-Pacific Insulin Biosimilars Sales by Application (2016-2026)
9.3 Asia-Pacific Insulin Biosimilars Market Size by Region
9.3.1 Asia-Pacific Insulin Biosimilars Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Insulin Biosimilars Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Insulin Biosimilars Sales by Type (2016-2026)
10.2 South America Insulin Biosimilars Sales by Application (2016-2026)
10.3 South America Insulin Biosimilars Market Size by Country
10.3.1 South America Insulin Biosimilars Sales in Volume by Country (2016-2026)
10.3.2 South America Insulin Biosimilars Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Insulin Biosimilars Sales by Type (2016-2026)
11.2 Middle East & Africa Insulin Biosimilars Sales by Application (2016-2026)
11.3 Middle East & Africa Insulin Biosimilars Market Size by Country
11.3.1 Middle East & Africa Insulin Biosimilars Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Insulin Biosimilars Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Insulin Biosimilars Typical Distributors
12.3 Insulin Biosimilars Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Insulin Biosimilars Revenue by Type, (USD Million), 2021-2026
Table 2. Global Insulin Biosimilars Revenue by Application, (USD Million), 2021-2026
Table 3. Sanofi S.A. Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi S.A. Major Business
Table 5. Sanofi S.A. Insulin Biosimilars Product and Services
Table 6. Sanofi S.A. Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 8. Boehringer Ingelheim Major Business
Table 9. Boehringer Ingelheim Insulin Biosimilars Product and Services
Table 10. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Eli Lilly & Co. Basic Information, Manufacturing Base and Competitors
Table 12. Eli Lilly & Co. Major Business
Table 13. Eli Lilly & Co. Insulin Biosimilars Product and Services
Table 14. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 16. Novo Nordisk A/S Major Business
Table 17. Novo Nordisk A/S Insulin Biosimilars Product and Services
Table 18. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Biocon Basic Information, Manufacturing Base and Competitors
Table 20. Biocon Major Business
Table 21. Biocon Insulin Biosimilars Product and Services
Table 22. Biocon Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Geropharm Basic Information, Manufacturing Base and Competitors
Table 24. Geropharm Major Business
Table 25. Geropharm Insulin Biosimilars Product and Services
Table 26. Geropharm Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 28. Wockhardt Major Business
Table 29. Wockhardt Insulin Biosimilars Product and Services
Table 30. Wockhardt Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Gan&Lee Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Gan&Lee Pharmaceuticals Major Business
Table 33. Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
Table 34. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. The United Laboratories International Basic Information, Manufacturing Base and Competitors
Table 36. The United Laboratories International Major Business
Table 37. The United Laboratories International Insulin Biosimilars Product and Services
Table 38. The United Laboratories International Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 40. Tonghua Dongbao Pharmaceutical Major Business
Table 41. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
Table 42. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Insulin Biosimilars Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Insulin Biosimilars Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Insulin Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Insulin Biosimilars Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Insulin Biosimilars Production Site of Key Manufacturer
Table 48. Insulin Biosimilars New Entrant and Capacity Expansion Plans
Table 49. Insulin Biosimilars Mergers & Acquisitions in the Past Five Years
Table 50. Global Insulin Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 51. Global Insulin Biosimilars Sales by Region (2021-2026) & (K Units)
Table 52. Global Insulin Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Insulin Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 55. Global Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 56. Global Insulin Biosimilars Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Insulin Biosimilars Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Insulin Biosimilars Price by Type (2016-2021e) & (US$/Unit)
Table 59. Global Insulin Biosimilars Price by Type (2021-2026) & (US$/Unit)
Table 60. Global Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 61. Global Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 62. Global Insulin Biosimilars Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Insulin Biosimilars Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Insulin Biosimilars Price by Application (2016-2021e) & (US$/Unit)
Table 65. Global Insulin Biosimilars Price by Application (2021-2026) & (US$/Unit)
Table 66. North America Insulin Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 67. North America Insulin Biosimilars Sales by Country (2021-2026) & (K Units)
Table 68. North America Insulin Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Insulin Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 71. North America Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 72. North America Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 73. North America Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 74. Europe Insulin Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 75. Europe Insulin Biosimilars Sales by Country (2021-2026) & (K Units)
Table 76. Europe Insulin Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Insulin Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 79. Europe Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 80. Europe Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 81. Europe Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 82. Asia-Pacific Insulin Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 83. Asia-Pacific Insulin Biosimilars Sales by Region (2021-2026) & (K Units)
Table 84. Asia-Pacific Insulin Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Insulin Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 87. Asia-Pacific Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 89. Asia-Pacific Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 90. South America Insulin Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 91. South America Insulin Biosimilars Sales by Country (2021-2026) & (K Units)
Table 92. South America Insulin Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Insulin Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 95. South America Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 96. South America Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 97. South America Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 98. Middle East & Africa Insulin Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 99. Middle East & Africa Insulin Biosimilars Sales by Country (2021-2026) & (K Units)
Table 100. Middle East & Africa Insulin Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Insulin Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Insulin Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 103. Middle East & Africa Insulin Biosimilars Sales by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa Insulin Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 105. Middle East & Africa Insulin Biosimilars Sales by Application (2021-2026) & (K Units)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Insulin Biosimilars Typical Distributors
Table 109. Insulin Biosimilars Typical Customers
List of Figures
Figure 1. Insulin Biosimilars Picture
Figure 2. Global Insulin Biosimilars Sales Market Share by Type in 2020
Figure 3. Rapid-Acting Biosimilars
Figure 4. Long-Acting Biosimilars
Figure 5. Premixed Biosimilars
Figure 6. Global Insulin Biosimilars Sales Market Share by Application in 2020
Figure 7. Type I Diabetes
Figure 8. Type II Diabetes
Figure 9. Global Insulin Biosimilars Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Insulin Biosimilars Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. Global Insulin Biosimilars Sales (2016-2026) & (K Units)
Figure 12. Global Insulin Biosimilars Price by Type (2016-2026) & (US$/Unit)
Figure 13. Global Insulin Biosimilars Production Capacity (2016-2026) & (K Units)
Figure 14. Global Insulin Biosimilars Production Capacity by Geographic Region: 2020 VS 2021
Figure 15. Insulin Biosimilars Market Drivers
Figure 16. Insulin Biosimilars Market Restraints
Figure 17. Insulin Biosimilars Market Trends
Figure 18. Global Insulin Biosimilars Sales Market Share by Manufacturer in 2020
Figure 19. Global Insulin Biosimilars Revenue Market Share by Manufacturer in 2020
Figure 20. Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. Top 3 Insulin Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 22. Top 6 Insulin Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 23. Global Insulin Biosimilars Sales Market Share by Region (2016-2026)
Figure 24. Global Insulin Biosimilars Revenue Market Share by Region (2016-2026)
Figure 25. North America Insulin Biosimilars Revenue (2016-2026) & (USD Million)
Figure 26. Europe Insulin Biosimilars Revenue (2016-2026) & (USD Million)
Figure 27. Asia-Pacific Insulin Biosimilars Revenue (2016-2026) & (USD Million)
Figure 28. South America Insulin Biosimilars Revenue (2016-2026) & (USD Million)
Figure 29. Middle East & Africa Insulin Biosimilars Revenue (2016-2026) & (USD Million)
Figure 30. Global Insulin Biosimilars Sales Market Share by Type (2016-2026)
Figure 31. Global Insulin Biosimilars Revenue Market Share by Type (2016-2026)
Figure 32. Global Insulin Biosimilars Price by Type (2016-2026) & (US$/Unit)
Figure 33. Global Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 34. Global Insulin Biosimilars Revenue Market Share by Application (2016-2026)
Figure 35. Global Insulin Biosimilars Price by Application (2016-2026) & (US$/Unit)
Figure 36. North America Insulin Biosimilars Sales Market Share by Type (2016-2026)
Figure 37. North America Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 38. North America Insulin Biosimilars Sales Market Share by Country (2016-2026)
Figure 39. North America Insulin Biosimilars Revenue Market Share by Country (2016-2026)
Figure 40. United States Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Canada Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Mexico Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Europe Insulin Biosimilars Sales Market Share by Type (2016-2026)
Figure 44. Europe Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 45. Europe Insulin Biosimilars Sales Market Share by Country (2016-2026)
Figure 46. Europe Insulin Biosimilars Revenue Market Share by Country (2016-2026)
Figure 47. Germany Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Insulin Biosimilars Sales Market Share by Region (2016-2026)
Figure 53. Asia-Pacific Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Insulin Biosimilars Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Insulin Biosimilars Revenue Market Share by Region (2016-2026)
Figure 56. China Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Korea Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Insulin Biosimilars Sales Market Share by Type (2016-2026)
Figure 63. South America Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 64. South America Insulin Biosimilars Sales Market Share by Country (2016-2026)
Figure 65. South America Insulin Biosimilars Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East & Africa Insulin Biosimilars Sales Market Share by Type (2016-2026)
Figure 69. Middle East & Africa Insulin Biosimilars Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Insulin Biosimilars Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Egypt Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. South Africa Insulin Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source

---